Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.53 |
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207906 | 0.88 | PTGS2 (0.49) | PTGS2PTGS1CACNA2D1MAPTHPGD | |
| SCHEMBL6885807 | 0.86 | PTGS2 (0.61) | PTGS2PTGS1 | |
| SCHEMBL5203782 | 0.86 | PTGS2 (0.61) | PTGS2PTGS1 | |
| SCHEMBL6132192 | 0.85 | PTGS2 (0.63) | PTGS2PTGS1TSHRNPSR1HPGD | |
| SCHEMBL6132484 | 0.85 | PTGS2 (0.63) | PTGS2PTGS1TSHRNPSR1HPGD | |
| SCHEMBL5202692 | 0.85 | PTGS2 (0.67) | PTGS2PTGS1TSHR | |
| SCHEMBL1115324 | 0.81 | PTGS2 (0.43) | PTGS2PTGS1CACNA2D1TSHRHPGD | |
| SCHEMBL6132473 | 0.81 | PTGS2 (0.67) | PTGS2PTGS1MAPTTSHRNPSR1 | |
| SCHEMBL1115042 | 0.79 | PTGS2 (0.47) | PTGS2PTGS1CACNA2D1MAPTSMN1; SMN2 | |
| SCHEMBL5865601 | 0.77 | PTGS2 (0.44) | PTGS2PTGS1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137739-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | ASTELLAS PHARMA, INC. | 2013-05-30 | — | — | US | disclosed |
| EP-2581084-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2013-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137739-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | CYP3A4, CYP3A43, CYP3A7 | PTGS2 3116/4885PTGS1 2201/4885CACNA2D1 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.